Synthesis of Azacarbolines via PhIO2-Promoted Intramolecular Oxidative Cyclization of α-Indolylhydrazones.

An unprecedented synthesis of polysubstituted indole-fused pyridazines (azacarbolines) from α-indolylhydrazones under oxidative conditions using a combination of iodylbenzene (PhIO2) and trifluoroacetic acid (TFA) has been developed. This transformation is conducted without the need for transition metals, harsh conditions, or an inert atmosphere.

Introduction

Selective carbon–nitrogen (C–N) bond formation is one of the most important processes in organic chemistry since it enables key steps in the synthesis of complex nitrogen-containing compounds from simple precursors.[1] Traditionally, methods for C–N bond construction were routinely focused on copper-catalyzed Ullmann–Goldberg,[2] Chan–Lam,[3] and Pd-catalyzed Buchwald–Hartwig[4] aminations using (pseudo)halocarbon or organometallic reagents. The recent maturation of methodologies (photochemical included) operating via transition-metal [Pd, Rh, Ru, Cu, etc.] catalyzed direct C–H bond amination[5] without prefunctionalization of simple starting materials offers a valuable alternative. However, these reactions generally suffer from high reaction temperature, narrow substrate scope, and high loading of the catalyst and/or metal oxidant. In addition, the contamination of heavy metals in the final product has limited their potential application in drug synthesis in the later stages. Hence, the development of alternative, effective, and safe metal-free methods for the formation of C–N bonds that can be performed at milder conditions starting from nonprefunctionalized simple precursor bonds is highly desirable. In this context, hypervalent iodine reagents[6] (HIRs) have captured our attention because of their inherent low toxicity, ready accessibility, low cost, high chemoselectivity, and mild conditions. Despite substantial advances in the oxidative C–H amination/amidation aiming at a greener goal,[7,8] to the best of our knowledge, the application of HIRs in the C(sp2)–H/N–H dehydrogenative coupling annulation reactions of hydrazone systems[9] to assemble N-heterocycles, especially those fused, still remains limited. Specifically, Tanimori’s[9a] and Zhu’s[9b] groups independently reported the synthesis of structurally diversified pyrazole/1H-indazole derivatives through metal-free oxidative C(sp2)–H cycloamination of both vinyl and aryl hydrazones (Figure a). Almost simultaneously, Chen, Xiao, and coauthors[9c] disclosed a PhI(OAc)2-promoted radical cyclization of allyl hydrazones for the assembly of a wide range of five-membered dihydropyrazoles (Figure b). Although an excellent example describing a copper-catalyzed intramolecular C–N bond formation to afford cinnolines has been reported by Xiao, Xu, and co-workers,[10] a metal-free approach to access a fused six-membered pyridazine skeleton from hydrazone substrates is yet to be realized.

Figure 1

Hypervalent iodine-promoted C(sp2)–H cycloamination of hydrazones.

Following our interest in the construction of polycyclic N-heterocycles[11] and aware of the privileged role of the indole nucleus in natural products and medicinal science,[12,13] we envisaged that the NH moiety in α-(indol-3-yl)hydrazones can be used as a N donor in coupling with the indole C2–H[7a,7i,14] bond in the presence of the hypervalent iodine reagents (HIRs) to construct fused indole pyridazines (Figure c).

Herein, we report an unprecedented example of PhIO2-promoted dehydrogenative cyclization of α-indolylhydrazones 1, whereby a sequential C–N bond formation, aromatization, N–C bond cleavage of a carbamate residue, ring expansion, and oxidative process are involved. Notably, this approach has resulted in a convenient assemblage of two biologically important heterocycles such as indole and pyridazine frameworks. The fusion of these two privileged heterocycles in one molecule[15] may create rigid entities endowed with either enhanced (synergistic effect) or new biological activities, which may feature promising bioactivity for screening. Furthermore, compared with Xiao and Xu’s protocol,[10] this method offers the clear advantage of not requiring the use of transition metal catalysts and harsh reaction conditions.

Results and Discussion

Generation of the required substrates 1 is readily achieved in 23–95% yields by ZnCl2-catalyzed reaction of the indoles with azoalkenes in CH2Cl2[16] (see Supporting Information). The intramolecular cyclization of α-indolylhydrazone 1a was initially investigated by applying Reddy’s conditions.[7e] To our satisfaction, the combination of PIDA with TFA (30 mol %) in CH2Cl2 at room temperature for 0.5 h afforded the product 2a in 56% yield (Table , entry 1). Conducting the reaction at 0 °C instead of ambient temperature resulted in a slower and lower conversion (entry 2). The replacement of TFA by diphenyl phosphoric acid (DPP) under identical reaction conditions also decreased the yield of 2a (entry 3). Additional variations of the initial conditions, including the use of I2 or Cu(OTf)2 as a promoter, led to poorer results (entries 4 and 5). It was also found that basic additives such as DBU and K2CO3 had a detrimental effect, as lower yields were achieved (entries 6 and 7). Whereas Cu(OTf)2 was crucial as an additive in previously reported iodine(III)-promoted oxidative C(sp2)–H cycloamination,[18] here it showed lower efficiency (entry 8). Though a more rapid consumption of α-indolylhydrazone 1a was observed with the use of a stoichiometric amount of TFA, the reaction only furnished 41% yield of the desired product 2a (entry 9). Solvents like CHCl3, CH3OH, CH3CN, and THF (entries 10–13) were substantially less efficient in terms of the product yield. While replacing PIDA with PIFA, HTIB (Koser’s reagent), or PhIO failed to furnish better results (entries 14–16), at the switching of PIDA to other hypervalent iodine(V) oxidants[19] such as IBX, DMP, and iodylbenzene (PhIO2), we were pleased to witness higher yields of 1a into 2a (entries 17–19). In particular, when PhIO2 as an uncommon iodine(V) reagent (λ5-iodane) was applied, the yield was improved to 82% (entry 19). A brief re-examination of the solvents still identified CH2Cl2 as optimal (entries 19–24). No improvement in yield was attained when the reaction was performed at 50 °C in DCE (entry 20) or when reducing the amount of PhIO2 to 1.5 equiv (entry 25).

Table 1

Optimization Studiesa

entry	oxidant (equiv)	additive (equiv)	solvent (2 mL)	time (h)b	yield (%)c
1	PIDA (2.3)	TFA (0.3)	CH2Cl2	0.5	56
2d	PIDA (2.3)	TFA (0.3)	CH2Cl2	4	43
3	PIDA (2.3)	DPP (0.3)	CH2Cl2	3	44
4	PIDA (2.3)	I2 (1.5)	CH2Cl2	1	<5
5	PIDA (2.3)	Cu(OTf)2 (0.1)	CH2Cl2	>24	17
6	PIDA (2.3)	DBU (1.2)	CH2Cl2	12	25
7	PIDA (2.3)	K2CO3 (1.2)	CH2Cl2	12	35e
8f	PIDA (2.3)	TFA (0.3)	CH2Cl2	0.5	51
9	PIDA (2.3)	TFA (1.0)	CH2Cl2	0.2	41
10	PIDA (2.3)	TFA (0.3)	CHCl3	0.5	55
11	PIDA (2.3)	TFA (0.3)	CH3OH	0.5	35
12	PIDA (2.3)	TFA (0.3)	CH3CN	0.5	40
13	PIDA (2.3)	TFA (0.3)	THF	1	43
14	PIFA (2.3)	TFA (0.3)	CH2Cl2	0.3	46
15	HTIB (2.3)	TFA (0.3)	CH2Cl2	5	<5
16	PhIO (2.3)	TFA (0.3)	CH2Cl2	3	37
17	IBX (2.3)	TFA (0.3)	CH2Cl2	4	79
18	DMP (2.3)	TFA (0.3)	CH2Cl2	12	64
19	PhIO2 (2.3)	TFA (0.3)	CH2Cl2	5	82
20g	PhIO2 (2.3)	TFA (0.3)	DCE	2.5	70
21	PhIO2 (2.3)	TFA (0.3)	THF	6	68
22	PhIO2 (2.3)	TFA (0.3)	CH3CN	6	65 (16)h
23	PhIO2 (2.3)	TFA (0.3)	HFIP	3	38
24	PhIO2 (2.3)	–	AcOH	1	47
25	PhIO2 (1.5)	TFA (0.3)	CH2Cl2	12	73 (9)h
26	–	TFA (0.3→1)	CH2Cl2	24i	0
27	PhIO2 (2.3)	–	CH2Cl2	24i	0 (5)h

All reactions were performed on a 0.2 mmol scale.

Denotes complete consumption of 1a unless otherwise noted.

Isolated yields.

Performed at 0 °C.

1-Methyl-1H-indole-2,3-dione[17] (12% yield) byproduct was also recovered.

Cu(OTf)2 (5 mol %) was added.

Performed at 50 °C.

Five-membered cross-coupled product C was also observed.

Denotes unreacted starting material. Abbreviations used: PIDA = phenyliodine diacetate, PIFA = phenyliodine bis(trifluoroacetate), HTIB = hydroxy(tosyloxy)iodobenzene, IBX = o-iodoxybenzoic acid [1-hydroxy-1,2-benziodoxol-3(1H)-one-1-oxide], DMP = Dess–Martin periodinate, DPP = diphenyl phosphoric acid, TFA = trifluoroacetic acid, AcOH = acetic acid, DBU = 1,8-diazabicyclo[5.4.0]undec-7-ene, DCE = 1,2-dichloroethane, THF = tetrahydrofuran, HFIP = hexafluoroisopropanol.

Control experiments also revealed that no product formation 2a was detected in the absence of PhIO2 (entry 26) or TFA (entry 27). This indicated that both PhIO2 and TFA were essential for the reaction to proceed smoothly. Therefore, the optimal reaction conditions can be summarized as follows: 0.2 mmol of substrate in CH2Cl2 (2 mL) with PhIO2 oxidant (2.3 equiv) and TFA additive (30 mol %) at room temperature for 5 h (Table ).

With the optimal conditions in hand, the substrate scope and the limitations of the oxidative intramolecular C–H amination with PhIO2 were investigated (Table ). An array of α-indolylhydrazones 1a–y were explored, resulting in the expected azacarbolines 2a–y in good to excellent yields. As shown in Table , various substituents on the azacarboline skeleton were accommodated. Although the ester (R3 = CO2Me, CO2Et, CO2i-Pr, CO2t-But, and CO2Allyl) or phosphonate (R3 = PO(OMe)2) groups in substrates 1 were well supported, the tolerance of amide (R3 = CON(Me)2) as well as the phenyl (R3 = Ph) group was lower. It was pleasing to find that incorporation of a bisindole moiety into the substrate proved a success, furnishing intriguing polyazaheterocyclic architecture 2j. The reaction conditions were also suitable for substrates bearing R4 alkyl groups, such as methyl, ethyl, and an n-propyl or ethyl acetate appendage. Various functional groups at the 4-, 5-, 6-, or 7-positions of the indole ring, regardless of electron-donating (Me, MeO, BnO) (2q–2s) and electron-withdrawing (Cl, Br, F, CO2Me) ones (2t–2x), were compatible with the optimized conditions. Furthermore, indole substrates with N-methyl, N-propyl, and N-benzyl (R1 = Me, n-Pr, Bn) substituents gave good yields of cyclized products. In contrast, the NH-free indole 1p proceeded with poor conversion (21% yield), probably due to its attenuate intrinsic reactivity. Pleasantly, azacarboline 2y incorporating a ring system between the N and C7 atoms of the indole ring was also prepared in good yield. It is important to note that this transformation allowed the installation of plural functionalities that are potentially well suited for future synthetic manipulations (for example, metal-catalyzed cross-coupling reactions, etc.). Interestingly, azacarboline with phosphorus substitution (2h) could serve as novel pharmaceuticals and agrochemicals.[20]

Table 2

Synthesis of Azacarbolines via Intramolecular Oxidative Indole C–H Amination Mediated by PhIO2a

Reactions were conducted on a 0.2 mmol scale in 2.0 mL of solvent.

Isolated yields.

3.0 mmol scale reaction (0.605 g).

Hydrazine tautomeric form.

The cycloamination reaction of 1a was also conducted on a 3 mmol scale, thus demonstrating the scalability of the present method (79% yield).

To gain insight into the reaction mechanism, we carried out further control experiments (Scheme ).

Scheme 1

Control Experiments

PBN = N-tert-butyl-α-phenylnitrone; TEMPO = (2,2,6,6-tetramethylpiperidin-1-yl)oxyl).

First, the application of N-tert-butyl-α-phenylnitrone (PBN)[21] or (2,2,6,6-tetramethylpiperidin-1-yl)oxyl (TEMPO)[9a] as a radical scavenger evidenced that the transformation of 1a to 2a was not suppressed (51% and 48% yield, respectively, Scheme a). This fact suggests that radical intermediates were not involved in this process. Second, the treatment of isolated five-membered cross-coupled product C (entries 22, 25, and 27, Table ) under the reaction conditions was found to give product 2a (Scheme b), the result of which indicated its effective involvement in the reaction mechanism. The preliminary formation of a less polar spot which gradually disappeared in favor of the final product 2a (TLC monitoring) also confirmed that C was the productive intermediate for this transformation. On the other hand, the same intermediate C did not work when subjected with PhIO2 alone (Scheme c). Third, when the prepared hydrolyzed pyrrolo[2,3-b]indole D1 was subjected under standard conditions, the expected 2b was successfully obtained (Scheme d). Lastly, substrate 1z with an amide N-protective group (CONH2) also furnished the corresponding azacarboline 2b in good yields (Scheme e).

Based on these results and in agreement with the previous references, a tentative mechanism for the oxidative C–H amination of α-indolylhydrazones is presented in Scheme .

Scheme 2

Tentative Mechanism for the Oxidative C–H Amination

Initially, PhIO2 reacts with 1a to give an N-iodo intermediate A after a CH/NH tautomerization (1,3-H shift). The subsequent electrophilic cyclization (oxidative C–N bond formation) step takes place between C-2 of the indole and nitrogen activated by the electrophilic iodine species generating intermediate B with simultaneous loss of PhIO and HO–. This was then followed by the formation of key pyrrolo[2,3-b]indole intermediate C through successive deprotonation and aromatization. Finally, the hydrolysis of a carbamic residue (intermediate D), ring expansion reaction,[22] and oxidative aromatization from E afford the desired azacarboline 2a. The explanation for the role of TFA is not immediately intuited, but its beneficial effect is clearly demonstrated in these latter steps (see Scheme b, 1c, and 1d).[22] However, considering that the transformation of intermediate C into 2a under standard conditions is not straightforward (32% yield, Scheme b), an alternative reaction pathway resulting from six-membered electrophilic cyclization may also be operative. In this case, the oxidative C–N bond formation would occur at the other nitrogen atom of the hydrazone residue, which could afford the final product 2a after undergoing the hydrolysis and oxidative aromatization steps.[23]

To further demonstrate the potential and synthetic usefulness of this method, the generated azacarbolines were transformed as shown in Scheme . The ester group at the 4-position of 2a could be easily hydrolyzed by treatment with KOH in methanol at reflux.[24] Decarboxylation was possible from 3 by heating at 140 °C in the presence of NaCl in DMSO/H2O.[25]

Scheme 3

Transformation of Generated Azacarbolines

Conclusion

In conclusion, we have developed a practical, environmentally friendly, and metal-free methodology for intramolecular oxidative cyclization of α-indolylhydrazones at room temperature. Complementary with existing methods, this approach allows direct access to scarcely represented azacarbolines[14] via dehydrogenative C(sp2)–N bond formation using the less emblazoned PhIO2[26,27] hypervalent iodine(V) reagent. We believe that obtaining of such fused N-heterocyclic scaffolds that incorporate both the privileged indole and pyridazine core with the aid of a “forgotten” PhIO2 through the not easy oxidative C–H/N–H cross coupling could open the way for further interesting novel applications.

Experimental Section

General Experimental Details

All the commercially available reagents and solvents were used without further purification. The following compounds were synthesized according to literature procedures: HTIB,[28] PhIO,[29] PhIO2,[30] IBX,[31] and DMP.[32]CAUTION! PhIO, PhIO2, and IBX are explosive under impact or heating to >200 °C, and appropriate precautions should be taken while handling these products. However, we have not experienced any explosions while working with these compounds at room temperature.

α-(Indol-3-yl)hydrazones 1a–i,k–z were prepared according to our previously reported methods[16a,16b] with a slight modification. Bis(indolyl)methane hydrazone 1j was prepared following literature procedure.[16c] Chromatographic purification of compounds was carried out on silica gel (60–200 μm). TLC analysis was performed on preloaded (0.25 mm) glass-supported silica gel plates (Kieselgel 60); compounds were visualized by exposure to UV light and by dipping the plates in 1% Ce(SO4)·4H2O and 2.5% (NH4)6Mo7O24·4H2O in 10% sulfuric acid followed by heating on a hot plate. All 1H NMR and 13C NMR spectra were recorded at 400 and 100 MHz using DMSO-d6 or CDCl3 as solvent on a Bruker Ultrashield 400 spectrometer (Bruker, Billerica, MA, USA). Chemical shifts (δ scale) are reported in parts per million (ppm) relative to the central peak of the solvent and are sorted in descending order within each group. The following abbreviations are used to describe peak patterns where appropriate: s = singlet, d = doublet, dd = doublet of doublets, dt = doublet of triplets, td = triplet of doublets, t = triplet, q = quartet, sex = sextet, sept = septet, m = multiplet, and br = broad signal. All coupling constants (J value) are given in Hertz [Hz]. High-resolution mass spectroscopy was performed on a Micromass Q-TOF Micro mass spectrometer (Micromass, Manchester, UK) using an ESI source. Melting points were determined in open capillary tubes and are uncorrected.

General Procedure for the Preparation of α-(Indol-3-yl)hydrazones 1a–i,k–z[16a,16b]

To a stirred mixture of indole (1.0 mmol) and azoalkene (1.5 mmol, 1.5 equiv) in dichloromethane (4 mL), zinc dichloride (13.6 mg, 0.1 mmol, 10 mol %) was added. (In order to obtain compound 1p, the addition of DIPEA (174 μL, 1 mmol, 1 equiv) was required.) After the disappearance of indole (TLC check), the solvent was removed, and the crude mixture was purified by column chromatography on silica gel to afford, after crystallization, the α-(indol-3-yl)hydrazones 1.

Procedure for the Preparation of Bis(indolyl)Methane Hydrazone 1j(16c)

1-Methylindole (0.75 mL, 6 mmol, 4 equiv) was added to a previously stirred solution of Na2CO3 (1.59 g, 15 mmol, 10 equiv) in water (5 mL). The dichloroacetone hydrazone (298.5 mg, 1.5 mmol) in dichloromethane (5 mL) was added, and the reaction mixture was stirred at room temperature. Upon completion of the reaction (1 h, TLC check), the mixture was diluted with water (10 mL) and extracted with dichloromethane (3 × 20 mL), and the collected organic phases were dried over anhydrous Na2SO4. After filtration, the reaction was concentrated in vacuo, and the obtained crude was purified by flash chromatography to afford the bis(indolyl)methane hydrazone 1j.

The NMR spectra in DMSO-d6 showed that compounds 1 exist predominantly in the hydrazone structure; however, signals related to the hydrazine tautomeric form can be also observed.

Methyl 2-(4-Methoxy-3-(1-methyl-1H-indol-3-yl)-4-oxobutan-2-lidene)hydrazinecarboxylate

Compound 1a was isolated by column chromatography (ethyl acetate/cyclohexane 50:50) in 68% yield (216.8 mg) for 1 h; white solid; mp 122–124 °C. 1H NMR (400 MHz, DMSO-d6) δ 9.88 (s, 1H), 7.47–7.43 (m, 1H), 7.43–7.39 (m, 1H), 7.32 (s, 1H), 7.19–7.13 (m, 1H), 7.04–7.00 (m, 1H), 4.87 (s, 1H), 3.80 (s, 3H), 3.68 (s, 6H), 1.79 (s, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 171.1, 154.5, 151.0, 136.5, 128.5, 126.8, 121.3, 119.0, 118.7, 109.8, 107.5, 51.9, 51.7, 51.3, 32.4, 14.4; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C16H20N3O4 318.1448; Found 318.1445.

Methyl 2-(4-Ethoxy-3-(1-methyl-1H-indol-3-yl)-4-oxobutan-2-ylidene)hydrazinecarboxylate

Compound 1b was isolated by column chromatography (ethyl acetate/cyclohexane 50:50) in 89% yield (294.0 mg) for 0.5 h; white solid; mp 119–121 °C. 1H NMR (400 MHz, DMSO-d6) δ 9.90 (s, 1H), 7.47–7.45 (m, 1H), 7.42–7.40 (m, 1H), 7.32 (s, 1H), 7.18–7.14 (m, 1H), 7.04–7.00 (m, 1H), 4.84 (s, 1H), 4.20–4.12 (m, 2H), 3.77 (s, 3H), 3.68 (s, 3H), 1.21 (t, J = 7.2 Hz, 3H), 1.79 (s, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 170.6, 154.6, 151.1, 136.5, 128.4, 126.8, 121.3, 119.0, 118.7, 109.8, 107.6, 60.6, 51.8, 51.4, 32.4, 14.4, 14.0; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C17H22N3O4 332.1605; Found 332.1611.

tert-Butyl 2-(4-Isopropoxy-3-(1-methyl-1H-indol-3-yl)-4-oxobutan-2-ylidene)hydrazinecarboxylate

Compound 1c was isolated by column chromatography (ethyl acetate/cyclohexane 20:80) in 84% yield (325.7 mg) for 1 h; white solid; mp 108–110 °C. 1H NMR (400 MHz, DMSO-d6) δ 9.51 (s, 1H), 7.46 (d, J = 8.0 Hz, 1H), 7.43–7.39 (m, 1H), 7.30 (s, 1H), 7.17–7.12 (m, 1H), 7.05–7.00 (m, 1H), 4.98 (sept, J = 6.4 Hz, 1H), 4.76 (d, J = 0.4 Hz, 1H), 3.77 (s, 3H), 1.76 (s, 3H), 1.45 (s, 9H), 1.21 (t, J = 6.4 Hz, 6H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 170.1, 153.1, 150.3, 136.5, 128.3, 126.9, 121.3, 118.9, 118.8, 109.8, 107.8, 73.1, 68.0, 51.6, 32.4, 28.1, 21.5, 14.4; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C21H30N3O4 388.2231; Found 388.2226.

tert-Butyl 2-(4-(tert-Butoxy)-3-(1-methyl-1H-indol-3-yl)-4-oxobutan-2-ylidene)hydrazinecarboxylate

Compound 1d was isolated by column chromatography (ethyl acetate/cyclohexane 20:80) in 95% yield (380.1 mg) for 7 h; orange solid; mp 91–93 °C. 1H NMR (400 MHz, DMSO-d6) δ 9.48 (s, 1H), 7.47 (d, J = 8.0 Hz, 1H), 7.40 (d, J = 8.4 Hz, 1H), 7.28 (s, 1H), 7.17–7.12 (m, 1H), 7.04–7.00 (m, 1H), 4.68 (s, 1H), 3.77 (s, 3H), 1.76 (s, 3H), 1.46 (s, 9H), 1.44 (s, 9H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 170.3, 153.6, 151.1, 137.0, 128.6, 127.4, 121.8, 119.4, 119.3, 110.2, 108.6, 81.2, 79.6, 52.9, 32.9, 28.6, 28.2, 14.8; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C22H32N3O4 402.2387; Found 402.2400.

Methyl 2-(4-(Allyloxy)-3-(1-methyl-1H-indol-3-yl)-4-oxobutan-2-ylidene)hydrazinecarboxylate

Compound 1e was isolated by column chromatography (ethyl acetate/cyclohexane 50:50) in 59% yield (203.9 mg) for 3 h; orange solid; mp 178–180 °C. 1H NMR (400 MHz, DMSO-d6) δ 9.91 (s, 1H), 7.46 (dt, J = 8.0, 0.8 Hz, 1H), 7.41 (dt, J = 8.0, 0.8 Hz, 1H), 7.33 (s, 1H), 7.16 (td, J = 8.0, 0.8 Hz, 1H), 7.02 (td, J = 8.0, 0.8 Hz, 1H), 5.99–5.89 (m, 1H), 5.32–5.27 (m, 1H), 5.21–5.18 (m, 1H), 4.90 (s, 1H), 4.65–4.62 (m, 2H), 3.77 (s, 3H), 3.68 (s, 3H), 1.79 (s, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 170.8, 155.1, 151.4, 137.0, 133.0, 129.0, 127.3, 121.8, 119.5, 119.3, 118.4, 110.3, 107.9, 65.5, 52.3, 51.8, 32.9, 15.0; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C18H22N3O4 344.1605; Found 344.1621.

tert-Butyl 2-(4-(Benzyloxy)-3-(1-methyl-1H-indol-3-yl)-4-oxobutan-2-ylidene)hydrazinecarboxylate

Compound 1f was isolated by column chromatography (ethyl acetate/cyclohexane 20:80) in 75% yield (325.6 mg) for 3 h; white solid; mp 118–120 °C. 1H NMR (400 MHz, DMSO-d6) δ 9.59 (s, 1H), 7.48 (d, J = 8.0 Hz, 1H), 7.41–7.30 (m, 7H), 7.17–7.11 (m, 1H), 7.00 (t, J = 7.4 Hz, 1H), 5.21 (d, J = 12.4 Hz, 1H), 5.15 (d, J = 12.4 Hz, 1H), 4.91 (s, 1H), 3.75 (s, 3H), 1.78 (s, 3H), 1.47 (s, 9H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 170.6, 163.6, 153.0, 136.5, 136.0, 128.6, 128.3, 128.1, 128.0, 127.9, 126.9, 121.3, 118.9, 109.7, 107.6, 79.1, 66.0, 51.4, 32.4, 28.1, 14.6; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C25H30N3O4 436.2231; Found 436.2234.

tert-Butyl 2-(4-(Dimethylamino)-3-(1-methyl-1H-indol-3-yl)-4-oxobutan-2-ylidene)hydrazinecarboxylate

Compound 1g was isolated by column chromatography (ethyl acetate/cyclohexane 30:70) in 82% yield (303.8 mg) for 24 h; white solid; mp 108–110 °C. 1H NMR (400 MHz, DMSO-d6) δ 9.42 (s, 1H), 7.45 (d, J = 8.0 Hz, 1H), 7.40 (d, J = 8.0 Hz, 1H), 7.24 (s, 1H), 7.17–7.13 (m, 1H), 7.03–7.00 (m, 1H), 5.02 (s, 1H), 3.76 (s, 3H), 2.88 (s, 3H), 2.87 (s, 3H), 1.73 (s, 3H), 1.45 (s, 9H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 170.4, 153.1, 136.6, 128.4, 126.8, 121.3, 118.9, 118.5, 109.8, 108.2, 79.0, 48.9, 37.0, 35.1, 32.4, 28.1, 14.9; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C20H29N4O3 373.2234; Found 373.2238.

Methyl 2-(1-(Dimethoxyphosphoryl)-1-(1-methyl-1H-indol-3-yl)propan-2-ylidene)hydrazinecarboxylate

Compound 1h was isolated by column chromatography (ethyl acetate/methanol 95:5) in 69% yield (261.9 mg) for 18 h; orange solid; mp 159–161 °C. 1H NMR (400 MHz, DMSO-d6) δ 9.92 (br, 1H), 7.57 (d, J = 8.0 Hz, 1H), 7.48 (d, J = 1.6 Hz, 1H), 7.41 (d, J = 8.0 Hz, 1H), 7.18–7.14 (m, 1H), 7.06–7.02 (m, 1H), 4.55 (d, 2JHP = 24.0 Hz, 1H), 3.79 (s, 3H), 3.68 (s, 3H), 3.67 (d, 3JHP = 10.4 Hz, 3H), 3.60 (d, 3JHP = 10.4 Hz, 3H), 1.85 (d, 4JHP = 1.2 Hz, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 154.7, 150.0, 136.3, 129.0 (d, 3JCP = 5.6 Hz), 127.3 (d, 2JCP = 10.5 Hz), 121.5, 119.0, 118.7, 109.8, 105.0 (d, 3JCP = 6.5 Hz), 53.0 (d, 2JCP = 6.8 Hz), 52.9 (d, 2JCP = 6.8 Hz), 51.9, 43.7 (d, 1JCP = 138.0 Hz), 32.5, 15.0 (d, 3JCP = 3.0 Hz); HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C17H23N3O5P 368.1370; Found 368.1368.

Methyl 2-(1-(1-Methyl-1H-indol-3-yl)-1-phenylpropan-2-ylidene)hydrazinecarboxylate

Compound 1i was isolated by column chromatography (ethyl acetate/cyclohexane 30:70) in 73% yield (244.2 mg) for 1 h; white solid; mp 179–181 °C. 1H NMR (400 MHz, DMSO-d6) δ 9.79 (s, 1H), 7.42–7.38 (m, 1H), 7.35–7.20 (m, 6H), 7.16–7.11 (m, 2H), 6.95 (t, J = 7.4 Hz, 1H), 5.19 (s, 1H), 3.75 (s, 3H), 3.66 (s, 3H), 1.85 (s, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 155.2, 141.5, 137.2, 128.9, 128.9, 128.7, 128.6, 127.5, 127.0, 121.7, 119.4, 119.1, 113.6, 110.1, 52.2, 51.4, 32.8, 15.8; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C20H22N3O2 336.1707; Found 336.1717.

Methyl 2-(1,1-Bis(1-methyl-1H-indol-3-yl)propan-2-ylidene)hydrazinecarboxylate

Compound 1j was isolated by column chromatography (ethyl acetate/cyclohexane 40:60) in 24% yield (142.0 mg) for 1 h; white solid; mp 188–190 °C. 1H NMR (400 MHz, DMSO-d6) δ 9.74 (s, 1H), 7.45 (d, J = 8.0 Hz, 2H), 7.40 (d, J = 8.4 Hz, 2H), 7.16 (s, 2H), 7.16–7.12 (m, 2H), 7.00–6.96 (m, 2H), 5.40 (s, 1H), 3.74 (s, 6H), 3.67 (s, 3H), 1.83 (s, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 155.6, 154.7, 136.7, 127.9, 127.1, 121.1, 119.0, 118.5, 113.1, 109.6, 51.7, 42.8, 32.3, 14.3; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C23H25N4O2 389.1972; Found 389.1979.

Methyl 2-(1-Methoxy-2-(1-methyl-1H-indol-3-yl)-1-oxopentan-3-ylidene)hydrazinecarboxylate

Compound 1k was isolated by column chromatography (ethyl acetate/cyclohexane 40:60) in 80% yield (264.1 mg) for 1 h; white solid; mp 124–126 °C. 1H NMR (400 MHz, DMSO-d6) δ 10.00 (s, 1H), 7.51–7.49 (m, 1H), 7.41–7.39 (m, 1H), 7.33 (s, 1H), 7.17–7.13 (m, 1H), 7.03–7.00 (m, 1H), 4.88 (s, 1H), 3.77 (s, 3H), 3.68 (s, 3H), 3.65 (s, 3H), 2.45–2.35 (m, 1H), 2.21–2.12 (m, 1H), 0.74 (t, J = 7.6 Hz, 3H). 13C{1H} NMR (100 MHz, DMSO-d6) δ 171.2, 154.5, 154.5, 136.5, 128.8, 127.0, 121.3, 119.0, 119.0, 109.7, 107.6, 51.8, 51.8, 49.9, 32.4, 21.0, 9.7; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C17H22N3O4 332.1605; Found 332.1598.

Methyl 2-(1-Methoxy-2-(1-methyl-1H-indol-3-yl)-1-oxohexan-3-ylidene)hydrazinecarboxylate

Compound 1l was isolated by column chromatography (ethyl acetate/cyclohexane 40:60) in 73% yield (251.8 mg) for 2 h; white solid; mp 124–126 °C. 1H NMR (400 MHz, DMSO-d6) δ 10.04 (s, 1H), 7.51–7.49 (m, 1H), 7.41–7.39 (m, 1H), 7.33 (s, 1H), 7.16–7.12 (m, 1H), 7.03–6.99 (m, 1H), 4.86 (s, 1H), 3.76 (s, 3H), 3.68 (s, 3H), 3.64 (s, 3H), 2.42–2.35 (m, 1H), 2.13–2.06 (m, 1H), 1.31–1.07 (m, 2H), 0.74 (t, J = 7.4 Hz, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 171.1, 154.4, 153.4, 136.5, 128.8, 127.0, 121.2, 119.0, 118.8, 109.6, 107.6, 51.7, 51.7, 50.0, 32.3, 29.7, 18.2, 13.7. HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C18H24N3O4 346.1761; Found 346.1752.

Diethyl 3-(2-(tert-Butoxycarbonyl)hydrazono)-2-(1-methyl-1H-indol-3-yl)pentanedioate

Compound 1m was isolated as a hydrazine tautomeric form by column chromatography (ethyl acetate/cyclohexane 40:60) in 75% yield (333.1 mg) for 3 h; white solid; mp 150–152 °C. 1H NMR (400 MHz, DMSO-d6) δ 10.18 (s, 1H), 9.08 (br, 1H), 7.38 (d, J = 8.4 Hz, 1H), 7.24 (d, J = 7.6 Hz, 1H), 7.12 (t, J = 7.4 Hz, 1H), 7.03 (s, 1H), 6.98 (t, J = 7.2 Hz, 1H), 4.00–3.92 (m, 4H), 3.75 (s, 3H), 3.12 (s, 2H), 1.41 (s, 9H), 1.11 (t, J = 7.2 Hz, 3H), 1.00 (t, J = 7.0 Hz, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 170.1, 168.7, 159.0, 156.9, 136.7, 130.1, 129.0, 121.3, 119.7, 119.0, 110.2, 110.0, 80.2, 60.8, 59.2, 35.9, 32.8, 28.5, 28.4, 14.8, 14.3; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C23H32N3O6 446.2286; Found 446.2298.

Methyl 2-(4-Methoxy-4-oxo-3-(1-propyl-1H-indol-3-yl)butan-2-ylidene)hydrazinecarboxylate

Compound 1n was isolated by column chromatography (ethyl acetate/cyclohexane 40:60) in 70% yield (242.8 mg) for 1 h; white solid; mp 116–118 °C. 1H NMR (400 MHz, DMSO-d6) δ 9.89 (s, 1H), 7.44 (t, J = 8.0 Hz, 2H), 7.36 (s, 1H), 7.15–7.11 (m, 1H), 7.02–6.99 (m, 1H), 4.86 (s, 1H), 4.14–4.10 (m, 2H), 3.68 (s, 3H), 3.67 (s, 3H), 1.76 (s, 3H), 1.75 (sex, J = 7.2 Hz, 2H), 0.82 (t, J = 7.2 Hz, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 171.1, 154.6, 151.0, 135.8, 127.6, 126.9, 121.3, 118.9, 118.8, 110.0, 107.5, 51.9, 51.8, 51.3, 47.0, 23.1, 14.3, 11.1; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C18H24N3O4 346.1761; Found 346.1767.

Methyl 2-(3-(1-Benzyl-1H-indol-3-yl)-4-methoxy-4-oxobutan-2-ylidene)hydrazinecarboxylate

Compound 1o was isolated by column chromatography (ethyl acetate/cyclohexane 50:50) in 44% yield (147.1 mg) for 3 h; white solid; mp 128–130 °C. 1H NMR (400 MHz, DMSO-d6) δ 9.93 (s, 1H), 7.53 (s, 1H), 7.46 (d, J = 8.0 Hz, 1H), 7.42 (d, J = 8.4 Hz, 1H), 7.32–7.28 (m, 2H), 7.25–7.23 (m, 1H), 7.21–7.17 (m, 2H), 7.12–7.08 (m, 1H), 7.03–6.99 (m, 1H), 5.42 (s, 2H), 4.91 (s, 1H), 3.68 (s, 3H), 3.68 (s, 3H), 1.79 (s, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 171.1, 154.6, 150.9, 138.1, 135.9, 128.5, 128.1, 127.3, 127.1, 126.9, 121.5, 119.2, 118.9, 110.3, 108.2, 52.0, 51.8, 51.3, 49.0, 14.4; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C22H24N3O4 394.1761; Found 394.1768.

Methyl 2-(3-(1H-Indol-3-yl)-4-methoxy-4-oxobutan-2-ylidene)hydrazinecarboxylate

Compound 1p was isolated by column chromatography (ethyl acetate/cyclohexane 30:70) in 23% yield (69.0 mg) for 6 h; whitish solid; mp 112–114 °C. 1H NMR (400 MHz, DMSO-d6) δ 11.11 (s, 1H), 9.90 (s, 1H), 7.42 (d, J = 8.0 Hz, 1H), 7.37 (d, J = 8.0 Hz, 1H), 7.31 (d, J = 2.4 Hz, 1H), 7.10–7.06 (m, 1H), 7.00–6.96 (m, 1H), 4.86 (s, 1H), 3.67 (s, 6H), 1.77 (s, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 171.3, 154.6, 151.2, 136.1, 126.5, 124.3, 121.3, 118.9, 118.5, 111.6, 108.3, 51.9, 51.8, 51.4, 14.4; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C15H18N3O4 304.1292; Found 318.1297.

Methyl 2-(3-(1,5-Dimethyl-1H-indol-3-yl)-4-methoxy-4-oxobutan-2-ylidene)hydrazinecarboxylate

Compound 1q was isolated by column chromatography (ethyl acetate/cyclohexane 40:60) in 76% yield (252.5 mg) for 0.25 h; white solid; mp 120–122 °C. 1H NMR (400 MHz, DMSO-d6) δ 9.90 (s, 1H), 7.29 (d, J = 8.4 Hz, 1H), 7.25 (s, 1H), 7.24–7.23 (m, 1H), 6.97 (dd, J = 8.4, 1.6 Hz, 1H), 4.82 (s, 1H), 3.73 (s, 3H), 3.67 (s, 3H), 3.67 (s, 3H), 2.36 (s, 3H), 1.79 (s, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 171.2, 154.6, 151.2, 135.0, 128.5, 127.5, 127.0, 123.0, 118.2, 109.6, 106.9, 52.0, 51.8, 51.2, 32.4, 21.3, 14.5; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C17H22N3O4 332.1605; Found 332.1593.

Methyl 2-(4-Methoxy-3-(5-methoxy-1-methyl-1H-indol-3-yl)-4-oxobutan-2-ylidene)hydrazinecarboxylate

Compound 1r was isolated by column chromatography (ethyl acetate/cyclohexane 40:60) in 62% yield (215.1 mg) for 0.5 h; white solid; mp 108–110 °C. 1H NMR (400 MHz, DMSO-d6) δ 9.92 (s, 1H), 7.30 (d, J = 9.2 Hz, 1H), 7.28 (s, 1H), 6.97 (d, J = 2.4 Hz, 1H), 6.80 (dd, J = 9.2, 2.4 Hz, 1H), 4.84 (s, 1H), 3.73 (s, 3H), 3.72 (s, 3H), 3.68 (s, 3H), 3.67 (s, 3H), 1.77 (s, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 117.2, 154.6, 153.4, 151.1, 131.8, 128.9, 127.2, 111.3, 110.6, 106.9, 100.8, 55.2, 52.0, 51.8, 51.3, 32.6, 14.4; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C17H22N3O5 348.1554; Found 348.1543.

Methyl 2-(3-(4-(Benzyloxy)-1-methyl-1H-indol-3-yl)-4-methoxy-4-oxobutan-2-ylidene)hydrazinecarboxylate

Compound 1s was isolated by column chromatography (ethyl acetate/cyclohexane 50:50) in 32% yield (133.6 mg) for 1 h; white solid; mp 129–130 °C. 1H NMR (400 MHz, DMSO-d6) δ 9.87 (s, 1H), 7.50–7.48 (m, 2H), 7.40–7.37 (m, 2H), 7.33–7.29 (m, 1H), 7.05–6.98 (m, 3H), 6.59 (d, J = 7.2 Hz, 1H), 5.22 (s, 1H), 5.19 (d, J = 12.4 Hz, 1H), 5.13 (d, J = 12.4 Hz, 1H), 3.72 (s, 3H), 3.64 (s, 3H), 3.48 (s, 3H), 1.88 (s, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 171.4, 154.5, 152.7, 151.1, 138.0, 137.2, 128.3, 127.5, 127.4, 126.9, 122.2, 116.9, 108.2, 103.2, 100.8, 69.1, 51.9, 51.7, 51.6, 32.6, 15.5; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C23H26N3O5 424.1867; Found 424.1872.

Methyl 2-(3-(7-Chloro-1-methyl-1H-indol-3-yl)-4-methoxy-4-oxobutan-2-ylidene)hydrazinecarboxylate

Compound 1t was isolated by column chromatography (ethyl acetate/cyclohexane 50:50) in 50% yield (174.6 mg) for 3 h; white solid; mp 130–132 °C. 1H NMR (400 MHz, DMSO-d6) δ 9.94 (s, 1H), 7.42 (d, J = 8.0 Hz, 1H), 7.39 (s, 1H), 7.14 (d, J = 7.6 Hz, 1H), 7.00–6.96 (m, 1H), 4.88 (s, 1H), 4.08 (s, 3H), 3.67 (s, 3H), 3.67 (s, 3H), 1.78 (s, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 170.9, 154.6, 150.6, 131.7, 131.4, 130.2, 122.8, 120.1, 118.2, 116.0, 108.0, 52.1, 51.8, 51.0, 36.2, 14.5; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C16H19ClN3O4 352.1059; Found 352.1054.

Methyl 2-(3-(4-Chloro-1-methyl-1H-indol-3-yl)-4-methoxy-4-oxobutan-2-ylidene)hydrazinecarboxylate

Compound 1u was isolated by column chromatography (ethyl acetate/cyclohexane 50:50) in 32% yield (113.6 mg) for 2 h; white solid; mp 148–150 °C. 1H NMR (400 MHz, DMSO-d6) δ 9.95 (s, 1H), 7.42 (dd, J = 8.0, 0.8 Hz, 1H), 7.22 (s, 1H), 7.16–7.12 (m, 1H), 7.05 (dd, J = 7.6 Hz, 0.8 Hz, 1H), 5.31 (s, 1H), 3.78 (s, 3H), 3.65 (s, 3H), 3.64 (s, 3H), 1.92 (s, 3H). Interconversion to the hydrazine tautomeric form occurred during the carbon spectrum acquisition, and as a result, two distinct sets of signals of both hydrazone and hydrazine tautomers (ca. 50:50) were observed in DMSO-d6 solution at 20 °C. 13C{1H} NMR (100 MHz, DMSO-d6) δ 171.3, 170.0, 162.2, 156.9, 154.5, 138.0, 137.7, 131.2, 130.1, 125.1, 124.7, 124.3, 123.4, 122.1, 121.6, 119.9, 119.4, 110.0, 109.4, 108.9, 108.1, 88.8, 52.2, 52.0, 51.8, 51.5, 50.4, 32.8, 32.6, 15.9, 15.9; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C16H19ClN3O4 352.1059; Found 352.1051.

Methyl 2-(3-(5-Bromo-1-methyl-1H-indol-3-yl)-4-methoxy-4-oxobutan-2-ylidene)hydrazinecarboxylate

Compound 1v was isolated by column chromatography (ethyl acetate/cyclohexane 50:50) in 39% yield (156.3 mg) for 1 h; white solid; mp 155–157 °C. 1H NMR (400 MHz, DMSO-d6) δ 9.94 (s, 1H), 7.64 (d, J = 1.6 Hz, 1H), 7.42–7.40 (m, 2H), 7.26 (dd, J = 8.8, 2.0 Hz, 1H), 4.89 (s, 1H), 3.77 (s, 3H), 3.67 (s, 3H), 3.67 (s, 3H), 1.78 (s, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 170.9, 154.6, 150.8, 130.3, 130.2, 128.6, 123.8, 121.3, 112.0, 111.7, 107.3, 52.0, 51.8, 51.0, 32.6, 14.7; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C16H19BrN3O4 396.0553; Found 396.0545.

Methyl 2-(3-(6-Fluoro-1-methyl-1H-indol-3-yl)-4-methoxy-4-oxobutan-2-ylidene)hydrazinecarboxylate

Compound 1w was isolated by column chromatography (ethyl acetate/cyclohexane 50:50) in 56% yield (187.2 mg) for 1 h; white solid; mp 140–142 °C. 1H NMR (400 MHz, DMSO-d6) δ 9.91 (s, 1H), 7.42 (dd, J = 8.8 Hz, 4JHF = 5.6 Hz, 1H), 7.33 (s, 1H), 7.29 (dd, 3JHF = 10.4 Hz, J = 2.4 Hz, 1H), 6.91–6.86 (m, 1H), 4.86 (s, 1H), 3.73 (s, 3H), 3.67 (s, 3H), 3.34 (s, 3H), 1.77 (s, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 171.0, 159.0 (d, 1JCF = 233.6 Hz), 154.5, 150.9, 136.6 (d, 3JCF = 12.3 Hz), 129.1 (d, 4JCF = 3.3 Hz), 123.5, 120.0 (d, 3JCF = 10.2 Hz), 107.9, 107.4 (d, 2JCF = 24.4 Hz), 96.2 (d, 2JCF = 25.9 Hz), 52.0, 51.8, 51.2, 32.6, 14.5; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C16H19FN3O4 336.1354; Found 336.1358.

Methyl 3-(1-Methoxy-3-(2-(methoxycarbonyl)hydrazono)-1-oxobutan-2-yl)-1-methyl-1H-indole-4-carboxylate

Compound 1x was isolated as the hydrazine tautomeric form by column chromatography (ethyl acetate/cyclohexane 50:50) in 64% yield (200.3 mg) for 1 h; white solid; mp 162–164 °C. 1H NMR (400 MHz, DMSO-d6) δ 10.22 (s, 1H), 9.45 (br, 1H), 7.62 (d, J = 8.4 Hz, 1H), 7.36 (d, J = 6.4 Hz, 1H), 7.21–7.17 (m, 2H), 3.80 (s, 3H), 3.71 (s, 3H), 3.64 (s, 3H), 3.36 (s, 3H), 1.67 (s, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 170.3, 169.2, 161.3, 157.4, 137.7, 133.0, 125.7, 124.8, 121.3, 120.3, 113.8, 110.8, 91.2, 52.6, 52.5, 50.6, 32.9, 16.1; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C18H22N3O6 376.1503; Found 376.1499.

Methyl 2-(3-(5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-methoxy-4-oxobutan-2-ylidene)hydrazinecarboxylate

Compound 1y was isolated by column chromatography (ethyl acetate/cyclohexane 50:50) in 44% yield (152.5 mg) for 1 h; white solid; mp 138–140 °C. 1H NMR (400 MHz, DMSO-d6) δ 9.90 (s, 1H), 7.31 (s, 1H), 7.22 (d, J = 8.0 Hz, 1H), 6.90 (t, J = 7.2 Hz, 1H), 6.94 (d, J = 7.2 Hz, 1H), 4.85 (s, 1H), 4.13 (t, J = 5.6 Hz, 2H), 3.68 (s, 3H), 3.67 (s, 3H), 2.90 (t, J = 6.0 Hz, 2H), 2.14–2.08 (m, 2H), 1.80 (s, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 171.3, 154.6, 151.3, 133.8, 125.8, 124.4, 121.9, 119.4, 118.3, 116.3, 107.5, 51.9, 51.8, 51.6, 43.4, 24.0, 22.3, 14.5; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C18H22N3O4 344.1605; Found 344.1604.

Ethyl 3-(2-Carbamoylhydrazono)-2-(1-methyl-1H-indol-3-yl)butanoate

The chemical–physical data of compound 1z are in agreement with those previously reported.[16b]

General Procedure for the Synthesis of Azacarbolines 2 via PhIO2-Mediated Intramolecular Oxidative Cyclization of α-Indolylhydrazones 1

To a stirred mixture of α-indolylhydrazone 1 (0.2 mmol) in dichloromethane (2 mL) were added PhIO2 (108.6 mg, 0.46 mmol, 2.3 equiv) and TFA (5 μL, 0.06 mmol, 30 mol %). After that, the solution was stirred overnight at room temperature. The crude product was directly purified by flash chromatography on silica gel (cyclohexane/ethyl acetate) to give the corresponding product 2.

Methyl 3,9-Dimethyl-9H-pyridazino[3,4-b]indole-4-carboxylate

Compound 2a was isolated by column chromatography (ethyl acetate/cyclohexane 50:50) in 82% yield (41.7 mg); yellow solid; mp 112–114 °C. 1H NMR (400 MHz, DMSO-d6) δ 8.12 (d, J = 8.0 Hz, 1H), 7.81–7.77 (m, 2H), 7.38–7.34 (m, 1H), 4.13 (s, 3H), 4.05 (s, 3H), 2.82 (s, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 166.6, 152.8, 146.8, 142.7, 131.2, 124.9, 121.7, 120.9, 115.9, 114.9, 110.5, 53.2, 28.1, 20.2; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C14H14N3O2 256.1081; Found 256.1078.

Ethyl 3,9-Dimethyl-9H-pyridazino[3,4-b]indole-4-carboxylate

Compound 2b was isolated by column chromatography (ethyl acetate/cyclohexane 50:50) in 75% yield (40.2 mg); yellow solid; mp 127–129 °C. 1H NMR (400 MHz, DMSO-d6) δ 8.13 (d, J = 8.0 Hz, 1H), 7.79–7.77 (m, 2H), 7.38–7.33 (m, 1H), 4.61 (q, J = 7.2 Hz, 2H), 4.04 (s, 3H), 2.82 (s, 3H), 1.42 (t, J = 7.2 Hz, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 166.1, 152.8, 146.7, 142.6, 131.1, 124.9, 122.1, 120.8, 115.9, 114.8, 110.5, 62.4, 28.1, 20.2, 13.9; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C15H16N3O2: 270.1237; Found 270.1240.

Isopropyl 3,9-Dimethyl-9H-pyridazino[3,4-b]indole-4-carboxylate

Compound 2c was isolated by column chromatography (ethyl acetate/cyclohexane 50:50) in 67% yield (38.1 mg); yellow solid; mp 105–107 °C. 1H NMR (400 MHz, DMSO-d6) δ 8.13 (d, J = 8.0 Hz, 1H), 7.82–7.76 (m, 2H), 7.41–7.33 (m, 1H), 5.47 (sept, J = 6.4 Hz, 1 H), 4.04 (s, 3H), 2.82 (s, 3H), 1.44 (d, J = 6.4 Hz, 6H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 165.6, 152.8, 146.4, 142.6, 131.1, 124.7, 122.5, 120.8, 115.9, 114.6, 110.6, 70.5, 28.1, 21.4, 20.0; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C16H18N3O2 284.1394; Found 284.1390.

tert-Butyl 3,9-Dimethyl-9H-pyridazino[3,4-b]indole-4-carboxylate

Compound 2d was isolated by column chromatography (ethyl acetate/cyclohexane 40:60) in 56% yield (33.4 mg); yellow solid; mp 160–162 °C. 1H NMR (400 MHz, DMSO-d6) δ 8.11 (d, J = 8.0 Hz, 1H), 7.80–7.76 (m, 2H), 7.41–7.35 (m, 1H), 4.04 (s, 3H), 2.81 (s, 3H), 1.69 (s, 9H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 165.4, 152.9, 146.2, 142.5, 131.0, 124.4, 123.4, 120.9, 115.9, 114.2, 110.6, 84.1, 28.1, 27.7, 19.9; HRMS (ESI/Q-TOF) m/z [M + H]+Calcd for C17H20N3O2 298.1550; Found 298.1561.

Allyl 3,9-Dimethyl-9H-pyridazino[3,4-b]indole-4-carboxylate

Compound 2e was isolated by column chromatography (ethyl acetate/cyclohexane 40:60) in 71% yield (39.8 mg); yellow solid; mp 102–104 °C. 1H NMR (400 MHz, DMSO-d6) δ 8.15 (dt, J = 8.0, 0.8 Hz, 1H), 7.80–7.78 (m, 2H), 7.37–7.33 (m, 1H), 6.20–6.10 (m, 1H), 5.53–5.48 (m, 1H), 5.40–5.36 (m, 1H), 5.10 (dt, J = 6.0, 1.2 Hz, 2H), 4.05 (s, 3H), 2.84 (s, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 165.8, 152.8, 146.7, 142.7, 131.6, 131.1, 124.9, 121.7, 120.7, 119.7, 115.9, 114.8, 110.5, 66.6, 28.1, 20.1; HRMS (ESI/Q-TOF) m/z: [M + H]+ Calcd for C16H16N3O2 282.1237; Found 282.1245.

Benzyl 3,9-Dimethyl-9H-pyridazino[3,4-b]indole-4-carboxylate

Compound 2f was isolated by column chromatography (ethyl acetate/cyclohexane 40:60) in 59% yield (39.0 mg); yellow solid; mp 132–134 °C. 1H NMR (400 MHz, DMSO-d6) δ 7.93 (d, J = 8.0 Hz, 1H), 7.78–7.41 (m, 2H), 7.47–7.38 (m, 3H), 7.58–7.54 (m, 2H), 7.24–7.19 (m, 1H), 5.64 (s, 2H), 4.03 (s, 3H), 2.79 (s, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 165.9, 152.8, 146.6, 142.6, 134.9, 131.1, 129.1, 128.7, 128.6, 124.9, 121.9, 120.7, 115.8, 114.8, 110.5, 67.9, 28.1, 20.1; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C20H18N3O2 332.1394; Found 332.1387.

N,N,3,9-Tetramethyl-9H-pyridazino[3,4-b]indole-4-carboxamide

Compound 2g was isolated by column chromatography (ethyl acetate/cyclohexane 100:0) in 46% yield (24.7 mg); yellow solid; mp 154–156 °C. 1H NMR (400 MHz, DMSO-d6) δ 7.82–7.72 (m, 3H), 7.38–7.32 (m, 1H), 4.04 (s, 3H), 3.24 (s, 3H), 2.77 (s, 3H), 2.67 (s, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 165.6, 152.5, 145.9, 142.1, 130.6, 126.2, 123.3, 120.9, 116.3, 113.9, 110.4, 36.7, 33.9, 28.0, 18.9; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C15H17N4O 269.1397; Found 269.1404.

Dimethyl (3,9-Dimethyl-9H-pyridazino[3,4-b]indol-4-yl)phosphonate

Compound 2h was isolated by column chromatography (ethyl acetate/cyclohexane 100:0) in 77% yield (46.8 mg); yellow solid; mp 137–139 °C. 1H NMR (400 MHz, DMSO-d6) δ 8.93 (d, J = 8.0 Hz, 1H), 7.82–7.75 (m, 2H), 7.39–7.33 (m, 1H), 4.05 (s, 3H), 3.76 (s, 3H), 3.73 (s, 3H), 3.03 (d, J = 1.2 Hz, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 152.2 (d, 2JCP = 11.0 Hz), 151.2 (d, 2JCP = 10.2 Hz), 143.1, 131.3, 127.9, 120.6, 120.1 (d, 3JCP = 8.8 Hz), 116.8, 116.7, 116.3 (d, 1JCP = 178.0 Hz), 110.1, 52.7 (d, 2JCP = 5.2 Hz), 28.1, 22.7; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C14H17N3O3P 306.1002; Found 306.1006.

3,9-Dimethyl-4-phenyl-9H-pyridazino[3,4-b]indole

Compound 2i was isolated by column chromatography (ethyl acetate/cyclohexane 40:60) in 46% yield (24.9 mg); yellow solid; mp 166–168 °C. 1H NMR (400 MHz, DMSO-d6) δ 7.73–7.59 (m, 5H), 7.56–7.49 (m, 2H), 7.11–7.03 (m, 2H), 4.03 (s, 3H), 2.56 (s, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 152.9, 149.0, 142.1, 135.2, 132.7, 129.9, 129.2, 128.9, 128.3, 123.5, 120.1, 117.5, 116.6, 110.2, 28.0, 20.0; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C18H16N3 274.1339; Found 274.1332.

3,9-Dimethyl-4-(1-methyl-1H-indol-3-yl)-9H-pyridazino[3,4-b]indole

Compound 2j was isolated by column chromatography (ethyl acetate/cyclohexane 90:10) in 67% yield (43.7 mg); orange solid; mp 106–108 °C. 1H NMR (400 MHz, DMSO-d6) δ 7.81 (s, 1H), 7.69 (d, J = 8.0 Hz, 1H), 7.66 (d, J = 8.0 Hz, 1H), 7.60–7.56 (m, 1H), 7.30–7.26 (m, 1H), 7.09 (d, J = 8.0 Hz, 1H), 7.02–7.00 (m, 2H), 6.98–6.94 (m, 1H), 4.05 (s, 3H), 3.99 (s, 3H), 2.66 (s, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 152.8, 150.8, 142.0, 136.7, 129.6, 129.5, 126.6, 125.8, 124.2, 121.9, 119.8, 119.7, 119.4, 118.0, 117.6, 110.7, 109.8, 107.5, 32.9, 28.0, 20.5; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C21H19N4 327.1604; Found 327.1593.

Methyl 3-Ethyl-9-methyl-9H-pyridazino[3,4-b]indole-4-carboxylate

Compound 2k was isolated by column chromatography (ethyl acetate/cyclohexane 50:50) in 80% yield (43.3 mg); yellow solid; mp 148–150 °C. 1H NMR (400 MHz, DMSO-d6) δ 8.05 (d, J = 8.0 Hz, 1H), 7.79–7.75 (m, 2H), 7.38–7.32 (m, 1H), 4.14 (s, 3H), 4.05 (s, 3H), 3.14 (q, J = 7.6 Hz, 2H), 1.34 (t, J = 7.6 Hz, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 166.6, 152.6, 151.2, 142.6, 131.0, 124.5, 121.5, 120.9, 115.9, 114.7, 110.5, 53.2, 28.1, 26.8, 14.7; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C15H16N3O2 270.1237; Found 270.1254.

Methyl 9-Methyl-3-propyl-9H-pyridazino[3,4-b]indole-4-carboxylate

Compound 2l was isolated by column chromatography (ethyl acetate/cyclohexane 40:60) in 76% yield (43.1 mg); yellow oil. 1H NMR (400 MHz, DMSO-d6) δ 8.04 (d, J = 8.0 Hz, 1 H), 7.81–7.74 (m, 2 H), 7.38–7.32 (m, 1H), 4.13 (s, 3H), 4.05 (s, 3H), 3.10 (t, J = 7.2 Hz, 2H), 1.76 (sex, J = 7.2 Hz, 2H), 0.94 (t, J = 7.2 Hz, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 166.7, 152.6, 150.1, 142.5, 131.1, 124.5, 121.9, 120.9, 115.9, 114.7, 110.6, 53.3, 35.2, 28.1, 23.2, 13.7; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C16H18N3O2 284.1394; Found 284.1408.

Ethyl 3-(2-Ethoxy-2-oxoethyl)-9-methyl-9H-pyridazino[3,4-b]indole-4-carboxylate

Compound 2m was isolated by column chromatography (ethyl acetate/cyclohexane 50:50) in 60% yield (41.3 mg); yellow solid; mp 102–104 °C. 1H NMR (400 MHz, DMSO-d6) δ 8.31 (dt, J = 8.0, 0.8 Hz, 1H), 7.81–7.77 (m, 2H), 7.39–7.33 (m, 1H), 4.54 (q, J = 7.2 Hz, 2H), 4.38 (s, 2H), 4.11 (q, J = 7.2 Hz, 2H), 4.05 (s, 3H), 1.39 (t, J = 7.2 Hz, 3H), 1.19 (t, J = 7.2 Hz, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 170.3, 165.5, 153.3, 145.1, 142.9, 131.4, 126.0, 122.2, 120.9, 116.2, 115.7, 110.5, 62.4, 60.7, 28.2, 14.0, 13.7; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C18H20N3O4 342.1448; Found 342.1439.

Methyl 3-Methyl-9-propyl-9H-pyridazino[3,4-b]indole-4-carboxylate

Compound 2n was isolated by column chromatography (ethyl acetate/cyclohexane 40:60) in 78% yield (44.2 mg); yellow solid; mp 144–146 °C. 1H NMR (400 MHz, DMSO-d6) δ 8.11 (d, J = 8.0 Hz, 1H), 7.83 (d, J = 8.0 Hz, 1H), 7.76 (dt, J = 7.2, 1.2 Hz, 1H), 7.35 (dt, J = 7.2, 1.2 Hz, 1H), 4.58 (t, J = 7.6 Hz, 2H), 4.13 (s, 3H), 2.82 (s, 3H), 1.86 (sex, J = 7.6 Hz, 2H), 0.88 (t, J = 7.6 Hz, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 166.5, 152.6, 146.7, 142.1, 131.1, 124.9, 121.8, 120.8, 115.9, 114.7, 110.7, 53.1, 43.0, 21.4, 20.1, 11.1; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C16H18N3O2 284.1394; Found 284.1399.

Methyl 9-Benzyl-3-methyl-9H-pyridazino[3,4-b]indole-4-carboxylate

Compound 2o was isolated by column chromatography (ethyl acetate/cyclohexane 40:60) in 76% yield (50.5 mg); yellow solid; mp 132–134 °C. 1H NMR (400 MHz, DMSO-d6) δ 8.13 (d, J = 8.0 Hz, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.73 (dt, J = 8.0, 1.2 Hz, 1H), 7.35 (dt, J = 8.0, 1.2 Hz, 1H), 7.31–7.21 (m, 5H), 5.87 (s, 2H), 4.13 (s, 3H), 2.83 (s, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 166.4, 152.7, 147.4, 141.9, 136.9, 131.3, 128.6, 127.5, 127.1, 125.1, 121.9, 121.2, 116.2, 115.1, 110.9, 53.3, 44.7, 20.2; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C20H18N3O2 332.1394; Found 332.1387.

Methyl 3-Methyl-9H-pyridazino[3,4-b]indole-4-carboxylate

Compound 2p was isolated by column chromatography (ethyl acetate/cyclohexane 30:70) in 21% yield (10.0 mg); yellow solid; mp 200–202 °C. 1H NMR (400 MHz, DMSO-d6) δ 12.53 (br, 1H), 8.09 (dt, J = 8.4, 0.8 Hz, 1H), 7.72–7.68 (m, 1H), 7.62–7.60 (m, 1H), 7.33–7.29 (m, 1H), 4.13 (s, 3H), 2.81 (s, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 166.7, 154.0, 146.6, 142.0, 131.1, 124.9, 121.7, 120.6, 116.4, 114.9, 112.2, 53.1, 20.2; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C13H12N3O2 242.0924; Found 242.0932.

Methyl 3,6,9-Trimethyl-9H-pyridazino[3,4-b]indole-4-carboxylate

Compound 2q was isolated by column chromatography (ethyl acetate/cyclohexane 50:50) in 79% yield (42.7 mg); yellow solid; mp 118–120 °C. 1H NMR (400 MHz, DMSO-d6) δ 7.84 (d, J = 1.2 Hz, 1H), 7.67 (d, J = 8.4 Hz, 1H), 7.60 (dd, J = 8.4, 1.2 Hz, 1H), 4.13 (s, 3H), 4.01 (s, 3H), 2.80 (s, 3H), 2.47 (s, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 166.7, 152.9, 146.6, 141.0, 132.6, 129.9, 124.4, 121.7, 115.9, 114.7, 110.4, 53.3, 28.2, 21.0, 20.2; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C15H16N3O2 270.1237; Found 270.1255.

Methyl 6-Methoxy-3,9-dimethyl-9H-pyridazino[3,4-b]indole-4-carboxylate

Compound 2r was isolated by column chromatography (ethyl acetate/cyclohexane 50:50) in 81% yield (46.1 mg); yellow solid; mp 117–119 °C. 1H NMR (400 MHz, DMSO-d6) δ 7.71 (d, J = 9.2 Hz, 1H), 7.53 (d, J = 2.4 Hz, 1H), 7.43 (dd, J = 9.2, 2.4 Hz, 1H), 4.13 (s, 3H), 4.00 (s, 3H), 3.85 (s, 3H), 2.82 (s, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 166.5, 153.9, 153.0, 146.5, 137.7, 121.4, 120.8, 116.1, 114.6, 111.5, 106.7, 55.5, 53.1, 28.2, 20.3; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C15H16N3O3 286.1186; Found 286.1183.

Methyl 5-(Benzyloxy)-9-methyl-9H-pyridazino[3,4-b]indole-4-carboxylate

Compound 2s was isolated by column chromatography (ethyl acetate/cyclohexane 50:50) in 80% yield (57.9 mg); yellow solid; mp 176–178 °C. 1H NMR (400 MHz, DMSO-d6) δ 7.60 (t, J = 8.4 Hz, 1H), 7.48–7.44 (m, 2H), 7.37–7.33 (m, 2H), 7.30–7.26 (m, 2H), 6.85 (d, J = 8.0 Hz, 1H), 5.46 (s, 2H), 3.99 (s, 3H), 3.79 (s, 3H), 2.69 (s, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 166.8, 155.9, 152.0, 145.8, 143.9, 136.5, 132.4, 128.5, 127.8, 127.4, 124.0, 112.6, 106.0, 103.7, 102.7, 69.5, 52.4, 28.3, 19.4; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C21H20N3O3 362.1499; Found 362.1505.

Methyl 8-Chloro-3,9-dimethyl-9H-pyridazino[3,4-b]indole-4-carboxylate

Compound 2t was isolated by column chromatography (ethyl acetate/cyclohexane 50:50) in 79% yield (45.8 mg); orange solid; mp 140–142 °C. 1H NMR (400 MHz, DMSO-d6) δ 8.00 (d, J = 8.0 Hz, 1H), 7.75 (d, J = 8.0 Hz, 1H), 7.28 (t, J = 8.0 Hz, 1H), 4.35 (s, 3H), 4.12 (s, 3H), 2.80 (s, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 166.2, 153.2, 147.5, 137.8, 132.5, 123.9, 122.0, 121.8, 119.1, 116.3, 114.2, 53.4, 31.2, 20.1; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C14H13ClN3O2 290.0691; Found 290.0697.

Methyl 5-Chloro-3,9-dimethyl-9H-pyridazino[3,4-b]indole-4-carboxylate

Compound 2u was isolated by column chromatography (ethyl acetate/cyclohexane 50:50) in 65% yield (37.4 mg); orange solid; mp 144–146 °C. 1H NMR (400 MHz, DMSO-d6) δ 7.77–7.72 (m, 2H), 7.39 (dd, J = 7.2, 1.6 Hz, 1H), 4.04 (s, 3H), 3.99 (s, 3H), 2.72 (s, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 167.1, 151.7, 146.2, 143.9, 131.7, 129.8, 124.3, 121.9, 114.1, 111.7, 109.6, 52.9, 28.6, 19.6; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C14H13ClN3O2 290.0691; Found 290.0705.

Methyl 6-Bromo-3,9-dimethyl-9H-pyridazino[3,4-b]indole-4-carboxylate

Compound 2v was isolated by column chromatography (ethyl acetate/cyclohexane 50:50) in 80% yield (53.7 mg); yellow solid; mp 131–133 °C. 1H NMR (400 MHz, DMSO-d6) δ 8.28 (d, J = 2.0 Hz, 1H), 7.93 (dd, J = 8.8, 2.0 Hz, 1H), 7.80 (d, J = 8.8 Hz, 1H), 4.13 (s, 3H), 4.04 (s, 3H), 2.86 (s, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 166.3, 152.9, 147.7, 141.6, 133.7, 127.5, 121.8, 117.7, 114.2, 112.8, 112.5, 53.3, 28.3, 20.6; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C14H13BrN3O2 334.0186; Found 334.0182.

Methyl 7-Fluoro-3,9-dimethyl-9H-pyridazino[3,4-b]indole-4-carboxylate

Compound 2w was isolated by column chromatograpy (ethyl acetate/cyclohexane 30:70) in 80% yield (43.5 mg); yellow solid; mp 188–190 °C. 1H NMR (400 MHz, DMSO-d6) δ 8.12 (dd, J = 8.8 Hz, 4JHF = 5.2 Hz, 1H), 7.66 (dd, 3JHF= 10.4 Hz, J = 2.4 Hz, 1H), 7.17–7.12 (m, 1H), 4.11 (s, 3H), 3.98 (s, 3H), 2.80 (s, 3H); 13C{1H} NMR (100 MHz, CDCl3) δ 167.2, 164.9 (d, 1JCF = 249.4 Hz), 154.1, 148.7, 144.7 (d, 3JCF = 12.5 Hz), 128.0 (d, 3JCF = 10.9 Hz), 121.8, 116.5, 113.6, 109.6 (d, 2JCF = 24.1 Hz), 96.6 (d, 2JCF = 26.8 Hz), 53.0, 28.5, 21.1; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C14H13FN3O2 274.0986; Found 274.0993.

Dimethyl 3,9-Dimethyl-9H-pyridazino[3,4-b]indole-4,5-dicarboxylate

Compound 2x was isolated by column chromatography (ethyl acetate/cyclohexane 50:50) in 73% yield (45.8 mg); brown solid; mp 136–138 °C. 1H NMR (400 MHz, DMSO-d6) δ 8.07 (dd, J = 8.4, 0.8 Hz, 1H), 7.87 (dd, J = 8.4, 7.6 Hz, 1H), 7.79 (dd, J = 7.6, 0.8 Hz, 1H), 4.12 (s, 3H), 3.93 (s, 3H), 3.91 (s, 3H), 2.85 (s, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 167.6, 166.4, 152.5, 147.3, 143.1, 130.4, 129.6, 123.4, 122.4, 114.6, 113.7, 113.5, 52.5, 52.5, 28.4, 20.7; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C16H16N3O4 314.1135; Found 314.1146.

Methyl 10-Methyl-5,6-dihydro-4H-pyridazino[4′,3′:4,5]pyrrolo[3,2,1-ij]quinoline-11-carboxylate

Compound 2y was isolated by column chromatography (ethyl acetate/cyclohexane 50:50) in 67% yield (37.5 mg); yellow solid; mp 130–132 °C. 1H NMR (400 MHz, DMSO-d6) δ 7.92 (d, J = 8.0 Hz, 1H), 7.50 (dd, J = 7.2, 0.8 Hz, 1H), 7.23 (dd, J = 8.0, 7.2 Hz, 1H), 4.46 (t, J = 6.0 Hz, 2H), 4.12 (s, 3H), 3.08 (t, J = 6.0 Hz, 2H), 2.83 (s, 3H), 2.24 (quint, J = 6.0 Hz, 2H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 166.6, 152.0, 146.8, 139.5, 128.6, 122.6, 122.6, 121.8, 120.7, 115.5, 114.1, 53.1, 40.2, 24.2, 21.2, 20.4; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C16H16N3O2 282.1237; Found 282.1239.

Methyl 1-((Methoxycarbonyl)amino)-2,8-dimethyl-1,8-dihydropyrrolo[2,3-b]indole-3-carboxylate

Intermediate C (entries 22, 25, and 27, Table ) was isolated as a byproduct by column chromatography (ethyl acetate/cyclohexane 40:60); mp 164–166 °C. 1H NMR (400 MHz, DMSO-d6) δ 10.99 (br, 1H), 7.93 (dd, J = 8.0, 0.8 Hz, 1H), 7.44 (d, J = 8.0 Hz, 1H), 7.19–7.14 (m, 1H), 7.12–7.08 (m, 1H), 3.89 (s, 3H), 3.79 (s, 6H), 2.48 (s, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 165.1, 156.2, 139.7, 136.5, 136.3, 120.6, 120.1, 119.7, 119.2, 109.5, 102.7, 102.1, 53.3, 50.9, 29.1, 10.2; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C16H18N3O4 316.1292; Found 316.1288.

Ethyl 1-Amino-2,8-dimethyl-1,8-dihydropyrrolo[2,3-b]indole-3-carboxylate

Compound D1 was isolated by column chromatography (ethyl acetate/cyclohexane 30:70) in 30% yield (22.5 mg); red solid; mp 168–170 °C. 1H NMR (400 MHz, DMSO-d6) δ 7.93–7.91 (m, 1H), 7.39 (d, J = 8.0 Hz, 1H), 7.12–7.08 (m, 1H), 7.06–7.02 (m, 1H), 6.02 (s, 2H), 4.31 (q, J = 7.2 Hz, 2H), 4.00 (s, 3H), 2.62 (s, 3H), 1.40 (t, J = 7.2 Hz, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 165.0, 139.9, 137.5, 137.4, 120.4, 119.8, 119.5, 118.6, 109.1, 102.1, 100.2, 58.9, 29.7, 14.7, 10.7; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C15H18N3O2 272.1394; Found 272.1388.

Hydrolysis of 2a

To a solution of 2a (127.6 mg, 0.5 mmol) in MeOH (5 mL) was added KOH (280.0 mg, 5 mmol, 10 equiv). The mixture was refluxed (heating mantle) until the disappearance of 2a (1.5 h, TLC check). The reaction mixture was cooled to r.t. and the solvent evaporated in vacuo. The residue was dissolved in water (2 mL) and acidified to pH 2 via the addition of 4 N aq HCl under stirring at 0 °C. The precipitate was filtered off, washed with diethyl ether, and dried to afford compound 3 as a yellow solid.

3,9-Dimethyl-9H-pyridazino[3,4-b]indole-4-carboxylic Acid

compound 3 was isolated in 95% yield (114.2 mg); yellow solid; mp 248–250 °C. 1H NMR (400 MHz, DMSO-d6) δ 14.57 (br, 1H), 8.22 (dt, J = 8.0, 0.8 Hz, 1H), 7.80–7.77 (m, 2H), 7.39–7.35 (m, 1H), 4.04 (s, 3H), 2.84 (s, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 167.2, 152.8, 146.4, 143.2, 131.6, 125.1, 124.5, 121.1, 116.1, 116.0, 110.7, 28.3, 19.5; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C13H12N3O2 242.0924; Found 242.0916.

Decarboxylation of 3

To a solution of compound 3 (48.2 mg, 0.2 mmol) in DMSO/water (10:1, 2 mL) was added NaCl (81.8 mg, 1.4 mmol, 7 equiv). The solution was stirred at 140 °C (oil bath) until the disappearance of the starting material (24 h, TLC check). After cooling to room temperature, the mixture was diluted with water (5 mL) and extracted with ethyl acetate (3 × 10 mL), washed with brine (10 mL), and dried over anhydrous sodium sulfate. The residue was purified by column chromatography on silica gel to give the product 4.

3,9-Dimethyl-9H-pyridazino[3,4-b]indole

Compound 4 was isolated by column chromatography (ethyl acetate/cyclohexane 20:80) in 92% yield (36.2 mg); light brown solid; mp 142–144 °C. 1H NMR (400 MHz, DMSO-d6) δ 8.31–8.30 (m, 1H), 8.28 (s, 1H), 7.74–7.69 (m, 2H), 7.36–7.32 (m, 1H), 3.98 (s, 3H), 2.78 (s, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 152.4, 150.7, 142.2, 130.4, 123.7, 120.4, 119.5, 118.0, 117.6, 110.2, 28.0, 21.5; HRMS (ESI/Q-TOF) m/z [M + H]+ Calcd for C12H12N3 198.1026; Found 198. 1031.